Ketamine One Announces 2021 AGSM Results

Rhea-AI Summary

KetamineOne Capital Limited (OTC: KONEF) announced the results of its annual general and special meeting held on December 17, 2021. Shareholders representing 15.69% of total shares voted to set the board of directors at four members, with all nominees elected to serve for the upcoming year. Key actions included the reappointment of auditors, approval of a restricted share unit plan, and authorization of previous grants of restricted share units, all receiving over 98% approval. The company aims to consolidate medical clinics and lead in mental health treatments across North America.

Positive

• 98.7% of votes were in favor of setting the number of directors at four.
• All director nominees were elected with over 98% approval.
• Reappointment of auditors received 100% approval.
• Restricted share unit plan authorized with 98.7% support.

Negative

• None.

VANCOUVER, British Columbia, Dec. 20, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce the results of voting at its annual general and special meeting of shareholders which was held on December 17, 2021 in Vancouver, British Columbia (the “Meeting”). There were 11 shareholders represented in person or by proxy at the Meeting holding 18,857,552 common shares, representing 15.69% of the Company’s total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting is set out below:

Number of Directors

As previously announced on December 15, 2021, Mr. Peter Nguyen resigned from the Company’s board of directors and will no longer stand for re-election. Therefore, the resolution to set the number of directors of the Company at four (4) was approved by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:

Votes For			Votes Against
#	%		#	%
18,612,552	98.7%		245,000	1.29%

        
Election of Directors

Each of the nominees for election as director listed in the Company’s management information circular dated November 12, 2021 were elected as directors of the Company for the ensuing year until their successors are elected or appointed. Voting results are set out below:

	Votes For			Votes Withheld
	#	%		#	%
James Henning	18,612,517	98.7%		245,035	1.29%
Natasha Raey	18,612,552	98.7%		245,000	1.29%
Brendan Purdy	18,606,942	98.7%		250,610	1.33%
Steven Inglefield	18,606,942	98.7%		250,610	1.33%

        Appointment of Auditors

Macias Gini & O’Connell, LLP, Chartered Professional Accountants were reappointed as Auditors of the Company for the ensuing year with their remuneration to be fixed by the Board of Directors. Voting results are set out below:

Votes For			Votes Withheld
#	%		#	%
18,857,552	100%		0	0%

        
Approval of Restricted Share Unit Plan

The resolution to authorize and approve the restricted share unit plan of the Company was approved by a majority of votes cast by the disinterested shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:

Votes For			Votes Against
#	%		#	%
18,607,027	98.7%		250,525	1.33%

        
Approval of Grant of Restricted Share Units

The resolution to authorize and approve the grant of restricted share units in September 2021 was approved by a majority of votes cast by the disinterested shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:

Votes For			Votes Against
#	%		#	%
18,606,992	98.7%		250,560	1.33%

ABOUT KETAMINE ONE

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of clinics across North America, with plans to further consolidate the highly fragmented industry. KGK Science Inc. is the Company’s wholly owned contract research division, which places it at the forefront of premium clinical research based on the subsidiary’s history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

On behalf of:

KETAMINE ONE

"Adam Deffett"
Adam Deffett, Interim CEO

For further information, please contact:

Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: IR@ketamine.one
Web: www.ketamine.one
Twitter: @KetamineOne

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

FAQ

What are the voting results from KetamineOne's meeting on December 17, 2021?

At the meeting, shareholders voted to set the board of directors at four and elected all nominees with over 98% approval.

What percentage of shareholders participated in KetamineOne's annual meeting?

15.69% of the total issued common shares were represented at the meeting.

What was approved regarding the auditors during KetamineOne's meeting?

Macias Gini & O’Connell, LLP were reappointed as auditors with 100% approval.

What was the outcome of the restricted share unit plan vote at the meeting?

The restricted share unit plan was approved with 98.7% of votes in favor.